Inactive Total Small Business Set-Aside (FAR 19.5)

The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality Research (OPQR), has a requirement for an Octet RH96 instrument that utili... The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality Research (OPQR), has a requirement for an Octet RH96 instrument that utilizes Biolayer Interferometry (BLI) to support high-throughput potency assays, antibody titer measurement (both whole and fragmented), host cell protein quantitation, residual Protein A detection, and kinetic analyses, as detailed in the attached Performance Work Statement (PWS).